Research Summary
Research Summary
FDA Review Time of New Drug Applications
Description
Study of FDA Review Time of New Drug Applications (NDAs) between 1990-2004. Three main questions are addressed: How the optimal innovation strategy for firms is contingent upon firm status positions in the knowledge domain; how knowledge status both enables and constrain's a firm's ability to depart from existing technology niches; and how the effects of external shocks on regulatory behavior are moderated by firm positions in the knowledge domain.